BioMarin says FDA to delay deciding on approval of DMD drug
(Reuters) - Drug developer BioMarin Pharmaceutical Inc said it was notified by the U.S. Food and Drug Administration that it would not be able to decide on the marketing of the company's lead drug as scheduled.
Aucun commentaire:
Enregistrer un commentaire